Oral Baricitinib Evaluated in RA Unresponsive to Conventional DMARDs
Eli Lilly and Incyte announced positive data from the pivotal study, RA-BEYOND, evaluating baricitinib vs. placebo for the treatment of rheumatoid arthritis (RA). Study findings were presented at the Annual European Congress of Rheumatology (EULAR 2016) in London.
RA-BEYOND is a long-term extension study which included RA patients who previously had an inadequate response or intolerance to ≥1 conventional DMARD and had not received a biologic DMARD, and completed the previous 24-week RA-BUILD study. Patients continued to receive the same dose of baricitinib 2mg or 4mg, or were switched to the 4mg dose after receiving placebo from the previous study. Structural joint damage was assessed after 24-weeks of treatment as measured by the van der Heijde modified Sharp scores.
Study data showed that treatment with baricitinib after 24 weeks demonstrated a statistically significant reduction in the progression of structural joint damage over placebo. Such treatment benefits were maintained through 48 weeks of therapy, with the most robust outcome observed with the 4mg dose.
Baricitinib is the only once-daily oral selective JAK1 and JAK2 inhibitor.
For more information call (800) 545-5979 or visit Lilly.com.